Novel orally active iron chelators (3-hydroxypyridin-4-ones) enhance the biliary excretion of plasma non-transferrin-bound iron in rats.

[1]  N. Mcintyre,et al.  Oxford Textbook of Clinical Hepatology , 1999 .

[2]  ScienceDirect.  Baillière's clinical haematology , 1998 .

[3]  N. Olivieri.  Long-term therapy with deferiprone. , 1996, Acta haematologica.

[4]  G. Koren,et al.  Iron-chelation therapy with oral deferiprone in patients with thalassemia major. , 1995, The New England journal of medicine.

[5]  R. Hider,et al.  Iron chelator design. , 1994, Advances in experimental medicine and biology.

[6]  D. van der Helm,et al.  Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. , 1993, Journal of medicinal chemistry.

[7]  G. Brittenham.  Development of iron-chelating agents for clinical use. , 1992, Blood.

[8]  A. Favier,et al.  Acute infusions of bile salts increase biliary excretion of iron in iron-loaded rats. , 1991, Gastroenterology.

[9]  R. Hider,et al.  Clinically useful chelators of tripositive elements. , 1991, Progress in medicinal chemistry.

[10]  A. Hoffbrand,et al.  Long‐term trial with the oral iron chelator 1,2‐dimethy1‐3‐hydroxypyrid‐4‐one (L1) II. CLINICAL OBSERVATIONS , 1990, British journal of haematology.

[11]  R. Hider,et al.  Update on the hydroxypyridinone oral iron-chelating agents. , 1990, Seminars in hematology.

[12]  B. Bacon,et al.  The pathology of hepatic iron overload: A free radical‐Mediated Process? , 1990, Hepatology.

[13]  R. Crichton.  Proteins of iron storage and transport. , 1990, Advances in protein chemistry.

[14]  R. Hider,et al.  2 The development of iron chelating drugs , 1989 .

[15]  R. Weisiger,et al.  Non-transferrin-bound iron uptake by rat liver. Role of membrane potential difference. , 1988, The Journal of biological chemistry.

[16]  C. Craven,et al.  Tissue distribution and clearance kinetics of non-transferrin-bound iron in the hypotransferrinemic mouse: a rodent model for hemochromatosis. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. Brissot,et al.  Characterization of non-transferrin-bound iron clearance by rat liver. , 1986, The Journal of biological chemistry.

[18]  N. LaRusso,et al.  Biliary excretion of iron from hepatocyte lysosomes in the rat. A major excretory pathway in experimental iron overload. , 1986, The Journal of clinical investigation.

[19]  P. Brissot,et al.  Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. , 1985, The Journal of clinical investigation.

[20]  B. Halliwell,et al.  Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. , 1985, Clinical science.

[21]  B. Bacon,et al.  Hepatic lipid peroxidation in vivo in rats with chronic iron overload. , 1983, The Journal of clinical investigation.

[22]  R. Gleason,et al.  Clinical consequences of acquired transfusional iron overload in adults. , 1981, The New England journal of medicine.

[23]  G. Herzberg.  Purification and properties of liver phosphofructokinase from normal and obese mice. , 1979, The International journal of biochemistry.

[24]  A. Bezkorovainy,et al.  Some aspects of iron uptake by rat hepatocytes in suspension. , 1979, The International journal of biochemistry.

[25]  E. Rachmilewitz,et al.  Non‐Specific Serum Iron in Thalassaemia: an Abnormal Serum Iron Fraction of Potential Toxicity , 1978, British journal of haematology.